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Abstract
Rationale: Pseudomonas aeruginosa undergoes phenotypic changes
during cystic fibrosis (CF) lung infection. Although mucoidy is
traditionally associated with transition to chronic infection, we
hypothesized that additional in vitro phenotypes correlate with this
transition and contribute to disease.
Objectives: To characterize the relationships between in vitro
P. aeruginosa phenotypes, infection stage, and clinical outcomes.
Methods: A total of 649 children with CF and newly identified
P. aeruginosa were followed for a median 5.4 years during which
a total of 2,594 P. aeruginosa isolates were collected. Twenty-six
in vitro bacterial phenotypes were assessed among the isolates,
including measures of motility, exoproduct production, colony
morphology, growth, and metabolism.
Measurements and Main Results: P. aeruginosa phenotypes
present at the time of culture were associated with both stage
of infection (new onset, intermittent, or chronic) and the primary
clinical outcome, occurrence of a pulmonary exacerbation (PE) in
the subsequent 2 years. Two in vitro P. aeruginosa phenotypes best
distinguished infection stages: pyoverdine production (31% of
new-onset cultures, 48%of intermittent, 69%of chronic) and reduced
protease production (31%, 39%, and 65%, respectively). The best
P. aeruginosa phenotypic predictors of subsequent occurrence of
a PE were mucoidy (odds ratio, 1.75; 95% confidence interval,
1.19–2.57) and reduced twitching motility (odds ratio, 1.43; 95%
confidence interval, 1.11–1.84).
Conclusions: In this large epidemiologic study of CF P. aeruginosa
adaptation, P. aeruginosa isolates exhibited two in vitro phenotypes
that best distinguished early and later infection stages. Among the
many phenotypes tested, mucoidy and reduced twitching best
predicted subsequent PE. These phenotypes indicate potentially
useful prognostic markers of transition to chronic infection and
advancing lung disease.
Keywords: epidemiology; risk factors; exacerbation; pulmonary
function; mucoid Pseudomonas aeruginosa
Airway infection and inflammation are key
contributors to lung disease in people with
cystic fibrosis (CF), and the opportunistic
gram-negative bacterium Pseudomonas
aeruginosa is among the most common and
important CF respiratory pathogens (1).
The association between P. aeruginosa
infection and measures of CF disease severity
is clearly established, including increased rate
of lung function decline, greater need for
antibiotics and hospitalization, and decreased
survival (2–10). Although there is a parallel
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between declining health and the progression
from early to chronic P. aeruginosa, gaps
remain in understanding the changes
that P. aeruginosa undergoes during this
critical transition period (11). P. aeruginosa
isolates have been observed to exhibit
a series of adaptive phenotypic and
genotypic changes during this progression,
but the relative roles of these changes in
pathogenesis and persistence are poorly
understood. These adaptations likely occur
in response to the host airway environment,
which includes specific nutrients; innate
and adaptive immune system components;
and medications, such as antibiotics (12).
An improved understanding of these
adaptations and their clinical consequences
is critical for defining how P. aeruginosa
persists and causes disease in the CF lung,
and for identifying novel therapeutic
approaches.
In perhaps the most extensive
longitudinal study of P. aeruginosa
phenotypic change, Li and coworkers (10)
followed 56 children with CF from birth to
16 years, describing the association between
the emergence of the best-characterized
in vitro P. aeruginosa phenotype, mucoidy,
and deterioration in chest radiograph scores
and pulmonary function. Prior studies have
identified numerous other P. aeruginosa
in vitro phenotypes that change throughout
infection (13), including colony morphology
(14); motility (15); cell signaling (16); and
production of pigments (17), proteases
(18, 19), and other exoproducts (19, 20).
However, these small studies, which each
generally focused on one P. aeruginosa
phenotype, were limited in their ability to
describe the interrelatedness of multiple
adaptive changes across the course
of P. aeruginosa infection and their
associations with clinical outcomes. For
example, although mucoidy has been
associated with failure of eradication by
antibiotic treatment in small, focused
studies (21), our subsequent comparative
analysis of many P. aeruginosa phenotypes
in a larger clinical population found other,
more common P. aeruginosa phenotypes
to be much more highly associated with this
outcome (22). To rigorously define the
natural history of P. aeruginosa phenotypic
changes, and the relationship between these
changes and disease progression, large
longitudinal studies comparing multiple
P. aeruginosa phenotypes are required (13).
Using longitudinally collected
P. aeruginosa isolates and clinical data from
a large, multicenter, prospective observational
study of P. aeruginosa infection among
a cohort followed across the transition from
early to chronic P. aeruginosa infection (23),
we defined the prevalence of multiple
P. aeruginosa phenotypes and their association
with disease progression. This study represents
the largest comparative study of P. aeruginosa
phenotypes to date. We hypothesized that
specific P. aeruginosa in vitro phenotypes
would increase in prevalence during the
transition from early to chronic infection
and correlate with measures of lung disease
severity, including frequency of pulmonary
exacerbations, emergence of mucoid
P. aeruginosa, and reduced lung function.
We chose phenotypic assays that could be
reproducibly performed by clinical laboratories
using commonly available resources. By
simultaneously comparing multiple in vitro
P. aeruginosa phenotypes with subsequent
clinical outcomes, we aimed to identify useful
candidate markers for the establishment of
chronic P. aeruginosa infection and CF lung
disease pathogenesis. Some of the results of
these studies have been previously reported in
the form of an abstract (24).
Methods
Study Design
The EPIC Observational Study is a
prospective, multicenter study investigating
risk factors for and outcomes of P. aeruginosa
acquisition in CF (23). Participants in
the current study had newly identified
P. aeruginosa within 6 months of enrollment
in the EPIC study or during the follow-up
period at the time this study was initiated,
termed “new-onset P. aeruginosa” and
defined as the first lifetime P. aeruginosa–
positive culture or the first positive after
greater than or equal to 2 years absence of
P. aeruginosa (with >1 negative culture per
year) (23). Respiratory cultures over the
follow-up period were performed at site
clinical microbiology laboratories as part
of standard clinical care, with results and
clinical data recorded in the CF Foundation
National Patient Registry (CFFNPR).
P. aeruginosa isolates were shipped from
site microbiology laboratories to a core
microbiology laboratory (23). This study was
approved by the Seattle Children’s Hospital
institutional review board.
Pseudomonas aeruginosa In Vitro
Phenotypic Characterization
Because of the large number of isolates
collected, and to maximize future use
for diagnostic microbiology laboratories,
phenotypic assays were selected for
simplicity and reproducibility in a high-
throughput format (see Figures E1 and E2
in the online supplement). All assays were
developed using P. aeruginosa strains
and isolates known to be competent and
defective for those specific phenotypes;
for quantitative assays, these strains were
included as controls. Phenotypes assessed
included motility (twitching, swimming),
exoproduct production (b-lactamase,
protease, and colorimetric assays for
pyoverdine and pyocyanin), colony
morphology (size, color, mucoidy, surface
wrinkliness, edge regularity, sectoring,
autolysis, sheen, Congo red binding),
and growth and metabolism (auxotrophy,
relative growth in added nitrate).
At a Glance Commentary
Scientific Knowledge on the
Subject: Pseudomonas aeruginosa
undergoes phenotypic changes during
cystic fibrosis (CF) lung infection, and
the mucoid phenotype is perhaps the
best-characterized change known to be
associated with poor clinical outcome.
Although numerous other adaptive
changes have been identified, it is
unclear from prior relatively small
studies how these changes are
associated with the transition from
early to chronic P. aeruginosa
infection, the relative prevalence of
these changes throughout the course
of infection, and whether any are
changes associated with markers
of disease pathogenesis.
What This Study Adds to the
Field: This study characterizes the
multiple in vitro phenotypic changes
that P. aeruginosa can undergo during
the transition from early to chronic
P. aeruginosa infection within the
setting of a large, prospective
observational study. Beyond describing
the phenotypic changes that occurred
most often throughout CF infection,
this study characterizes their relative
clinical importance through their
association with outcomes reflective
of CF disease pathogenesis.
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Endpoints
Phenotype prevalence at time of culture,
defined as present if exhibited by any isolate
from the same culture, was stratified by stage
of infection: (1) new-onset P. aeruginosa;
(2) chronic P. aeruginosa, defined as the
third positive P. aeruginosa culture within
a 2-year period (modified Leeds criteria,
requiring at least two P. aeruginosa
culture-positive quarters within a year
to meet the definition [25, 26]); and (3)
intermittent P. aeruginosa, defined as
neither new onset or chronic. Although
isolates were not available from every
P. aeruginosa–positive culture identified
over the follow-up period, infection
stage at the time of each culture for
which an isolate was available was
defined in reference to all observed
P. aeruginosa–positive cultures during
the study as recorded in the CFFNPR,
not only those for which isolates were
available. The primary clinical outcome
was occurrence of a physician-defined
pulmonary exacerbation requiring
intravenous (IV) antibiotics and/or
hospitalization during the 2 years after
each culture, chosen to reflect a clinically
relevant time period and to reflect the
available follow-up time after the collection
of isolates obtained later in the study.
Secondary endpoints included the
emergence or reappearance of mucoid
P. aeruginosa as recorded in the CFFNPR,
and change in FEV1 % predicted.
Statistical Analyses
Repeated measures logistic regression
models were used to identify phenotypes
that best distinguished between one
infection stage and another (27), and
phenotypes that distinguished between
infection stages at a 0.05 level two-sided
error for all three infection stage
comparisons were identified (equivalent
to a type 1 error ,0.053 = 0.0001).
Multivariable repeated measures logistic
or linear regression models were used to
identify phenotypes significantly associated
with outcomes of interest.
Results
Cohort Description
A total of 649 EPIC Observational Study
participants had at least one P. aeruginosa
isolate available at the core microbiology
laboratory and comprised the current
cohort. Characteristics at the time of
new-onset P. aeruginosa, which occurred
between 2004 and 2011, are described in
Table 1. The median follow-up time after
new-onset P. aeruginosa among the study
cohort was 5.4 years (maximum follow-up,
7.0 years), during which 2,594 P. aeruginosa
isolates were obtained and phenotyped
from 1,707 P. aeruginosa–positive
respiratory cultures (representing z54%
of all P. aeruginosa–positive cultures during
the follow-up period). A total of 51 of those
2,594 isolates grew too poorly in vitro
to be phenotyped in any assay and were
considered “absent” for this analysis. The
average number of cultures per participant
from which isolates were collected was
2.63 (median, 2; range, 1–16). There were
602 participants in the EPIC Observational
Study with new-onset P. aeruginosa for
whom no P. aeruginosa isolates were
available and who were therefore not
included in the current cohort; these
participants were on average slightly
older, but comparable with the
current study cohort with respect
to other characteristics (Table E1).
Antipseudomonal therapy at the time
of new-onset P. aeruginosa in the EPIC
Observational Study cohort has been
previously described, with approximately
91% receiving antipseudomonal antibiotics
within the first 6 months after initial




Figure 1A displays the availability of
P. aeruginosa cultures from which isolates
were sampled by age and infection stage. A
total of 580 cultures representing new-onset
P. aeruginosa from 580 of 649 (89%)
participants were sampled, 459 cultures
categorized as reflecting intermittent
P. aeruginosa infection from 307 (47%)
participants, and 668 cultures categorized
as chronic from 211 (33%) participants.
Overall, 57% of the 1,707 cultures were
oropharyngeal (OP), 20% from sputum,
1% from bronchoalveolar lavage, and 22%
had missing culture source; OP cultures
were more commonly used at new-onset
infection as compared with persistent
(Table E2). The average age at new-onset
P. aeruginosa culture was 6.3 years, 8.1
years at the time of an intermittent culture,
and 10.8 years at the time of a chronic
culture. Figure 1B displays the prevalence
of each phenotype by infection stage (see
Figure E3 for prevalence by age group).
The most prevalent phenotypes among the
new-onset cultures were tan colony color
(67%), pyocyanin production (49%), green
broth color (37%), and abnormal colony
size (36%). Across infection stage, mucoidy
was present among 8% of new-onset
cultures, 14% of intermittent cultures,
and 29% of chronic cultures, and further
Table 1. Description of the Study Cohort at New-Onset Pseudomonas
aeruginosa (n = 649)
N (%) or Mean (SD)
Sex, male 325 (50%)
Age at new-onset P. aeruginosa, yr 6.3 (3.86)
Age distribution at new-onset P. aeruginosa
.0–3 yr 166 (26%)
.3–6 yr 147 (23%)
.6–12 yr 280 (43%)
.12 yr 56 (9%)
Genotype
F508 del heterozygous 233 (36%)





Black/African American 17 (3%)
Other 13 (2%)
First lifetime P. aeruginosa 1 culture at new onset 389 (60%)
FEV1 % predicted* 94% (18)
*A total of 266 participants had FEV1 % predicted measurement at time of new-onset P. aeruginosa.
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analyses demonstrated these prevalence
estimates did not differ significantly by
lifetime P. aeruginosa history (i.e., between
participants with no prior P. aeruginosa vs.
those with P. aeruginosa detected >2 years
before enrollment). By comparison, several
other in vitro phenotypes exhibited more
significant differences in prevalence across
infection stages (e.g., were more prevalent in
cultures categorized as chronic as compared
with intermittent, and more prevalent in
intermittent cultures as compared with new
onset). Phenotypes demonstrating greater
prevalence and differentiation among
infection stages in Figure 1B included
pyoverdine production, reduced protease
production, reduced twitching motility, and
reduced swimming motility.
Figure 2 is a schematic of the
phenotypes with significantly higher
odds of occurring during one infection
stage than another based on multivariable
modeling. Two phenotypes, pyoverdine
production and reduced protease
production, were significantly different
across all three infection stage comparisons.
As shown in Figure 2, reduced protease
production and intact pyoverdine production
were associated with significantly higher
odds of occurring during chronic infection
as compared with new onset (odds ratio
[OR], 3.24; 95% confidence interval [CI],
2.31–4.56 and OR, 4.04; 95% CI, 2.99–5.47,
respectively), with similar findings in the
other two infection stage comparisons.
Further modeling demonstrated a “dose-
response” across infection stages with
respect to reduced protease; in other words,
there were significantly higher odds of
a culture exhibiting reduced protease
among at least one isolate during chronic
and intermittent infection as compared
with new-onset infection (OR comparing
chronic vs. new-onset infection, 4.1; 95%
CI, 3.1–5.5; OR comparing intermittent vs.
new onset, 1.4; 95% CI, 1.1–1.9). Similarly,
there were significantly higher odds of
a culture exhibiting pyoverdine production
during chronic and intermittent infection
as compared with new-onset infection
(OR comparing chronic vs. new onset,
5.0; 95% CI, 3.8–6.5; OR comparing






Although there was clear evidence for
in vitro phenotypic changes distinguishing
stage of infection, another aim of our study
was to assess whether these phenotypes
were associated with clinical outcomes
reflecting morbidity. Table 2 presents
results from the multivariable model
used to identify phenotypes significantly
associated with the occurrence of
a pulmonary exacerbation requiring
hospitalization and/or IV antibiotics in the
following 2 years. The model was adjusted
for time from new-onset infection to
identify phenotypes that were associated
with poor clinical outcome not solely
caused by the fact that they were more
prevalent during later infection. Mucoidy
had the strongest association with the
subsequent occurrence of a pulmonary
exacerbation (OR, 1.75; 95% CI, 1.19–2.57),
followed closely by defective twitching
motility (OR, 1.43; 95% CI, 1.11–1.84).
Univariate regression analyses indicated
that defective swimming motility was also
significantly associated with pulmonary
exacerbations but was highly correlated
with defective twitching, the latter of which
was the better predictor in multivariable
regression modeling. Although other
phenotypes, particularly those more
prevalent later in infection, such as
reduced protease production, demonstrated
significant univariate associations with
the occurrence of a pulmonary exacerbation
Figure 1. (A) Pseudomonas aeruginosa cultures from which isolates were sampled from by age and infection stage. Each horizontal plane represents
a single participant in the study cohort. (B) Prevalence of each phenotype by infection stage (corresponding percentages provided in Table E3).
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(Figure E4), no other phenotypes besides
mucoidy and reduced twitching motility
were significantly associated with pulmonary
exacerbations in the multivariable model
after adjusting for time from infection.
Additional sensitivity analyses revealed that
mucoidy and reduced twitching motility
remained significantly associated with the
occurrence of an exacerbation over both
a 6-month and 1-year follow-up period.
Association between Phenotypes
and Emergence or Reappearance
of Mucoidy
The significant association between
mucoidy and subsequent pulmonary
exacerbation observed here underscored
the clinical importance of this phenotype.
Because mucoidy commonly emerges
relatively late during chronic infection,
phenotypic predictors of the subsequent
emergence of mucoidy may be clinically
useful. Table 3 presents multivariable
model results for the association between
phenotypes and the reappearance or new
Figure 2. Results from the three multivariable models used to identify the set of phenotypes best distinguishing one infection stage from another. The set
of phenotypes significantly associated with the more “advanced” infection stage as compared with the less advanced infection stage as identified using
multivariable, repeated measures logistic regression. For example, reduced protease had significantly higher odds of being present during chronic
infection as compared with new-onset infection (odds ratio [OR], 3.24), in addition to significantly higher odds of being present in chronic infection as
compared with intermittent infection (OR, 1.95) and in intermittent infection as compared with new-onset infection (OR, 1.73). Bold phenotypes (reduced
protease and pyoverdine production) showed significance across all three comparisons. C.I. = confidence interval.
Table 2. Results from a Multivariable Model for the Association between Phenotypes
and the Occurrence of a Pulmonary Exacerbation Requiring Intravenous Antibiotics
and/or Hospitalization over the Following Two Years
Odds Ratio 95% CI P Value
Mucoidy
Nonmucoid — — —
Mucoid 1.75 1.19–2.57 0.004
Twitching
Normal — — —
Reduced/none 1.43 1.11–1.84 0.006
Time from new-onset infection, yr 1.03 0.96–1.10 0.427
Definition of abbreviation: CI = confidence interval.
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emergence of mucoidy over the following
2 years. Included in the model was the
presence of mucoidy at any time point,
which was highly associated with its
reappearance over the following 2-year
period (OR, 6.04; 95% CI, 4.14–8.81).
Two additional phenotypes were associated
with the emergence of mucoidy even after
adjusting for time from infection, which
itself was significantly associated with
increased odds of developing mucoidy
(OR, 1.31; 95% CI, 1.21–1.41). The
presence of increased growth in nitrate and
b-lactamase activity were independently
associated with increased odds of future
mucoidy (OR, 2.37; 95% CI, 1.65–3.40 and
OR, 1.68; 95% CI, 1.20–2.34, respectively).
After adjusting for time from new-onset
infection, several phenotypes that were
associated with the emergence or
reappearance of mucoidy in unadjusted
univariate analyses (Figure E5) were no
longer significant, suggesting a strong
relationship between these phenotypes
and duration of infection.
Association between Pseudomonas
aeruginosa Phenotypes and
Subsequent Change in Lung Function
No phenotypes were significantly associated
with the subsequent 2-year change in FEV1 %
predicted, although mucoidy exhibited
a nonsignificant trend toward association
with more rapid decline in lung function
during chronic infection as compared
with new-onset or intermittent infection
(Tables E5 and E6). The 2-year change
in FEV1 % predicted associated with
mucoidy observed at new-onset infection
was 2.11% (95% CI, 23.49 to 7.71), as
compared with a 1.57% decline during
intermittent infection (95% CI, 26.43%
to 3.30%) and a 3.01% decline during
chronic infection (95% CI, 27.02% to
1.01%). Of note, infection stage was not
independently associated with significant
2-year changes in FEV1 % predicted in
this model.
Discussion
Among the largest cohort of individuals
with CF for whom P. aeruginosa in vitro
phenotypes have been characterized, this
study identified the phenotypic changes
most associated with stage of P. aeruginosa
infection and defined the associations
between these phenotypes and clinical
outcomes. Surprisingly, we found that
even at the earliest stages of P. aeruginosa
detection in children with CF, many in vitro
phenotypes occurred frequently that
were previously considered to represent
adaptation during chronic infection.
Despite the highly diverse and dynamic
in vitro phenotypes exhibited by
P. aeruginosa isolates, only a limited
number of phenotypes were associated with
measures of the progression of infection
and lung disease. Although the prevalence
of mucoidy increased during the course
of infection, other in vitro phenotypic
changes performed better at distinguishing
new-onset, intermittent, and chronic
P. aeruginosa infection periods. However,
the most important finding of our study
was the identification of P. aeruginosa
phenotypes most associated with key
clinical outcomes in CF that, surprisingly,
were not always those that occurred later
in infection.
The two P. aeruginosa phenotypes
that best distinguished infection stages,
pyoverdine production and reduced
protease activity, have been studied before.
We previously reported production of both
pyoverdine and protease (among other
phenotypes) to be decreased in late versus
early infection isolates in a clonal lineage
from one patient with CF (28), and
both phenotypes were observed to vary
among seven CF chronic infection isolates
in one lineage (29). In the current large,
comparative phenotypic study, these
two phenotypes significantly differed in
prevalence across initial, intermittent, and
chronic infection stages. Both in vitro
phenotypes, as for all characteristics
tested in this study, can be easily and
reproducibly measured by clinical
laboratories, underscoring their potential
clinical use as markers of the transition
from early to chronic infection (a role
traditionally played by mucoidy).
Despite the striking variety of
in vitro phenotypic changes undergone
by P. aeruginosa, our results found very
few of these phenotypes to be associated
with symptomatic lung disease. Although it
must be noted that bacterial characteristics
measured in vitro are not necessarily
representative of behavior in vivo, only
the characteristics that can be robustly
measured ex vivo represent candidate
disease markers. The primary outcome
in this study, occurrence of a pulmonary
exacerbation requiring IV antibiotics
and/or hospitalization within 2 years,
was chosen for its demonstrated
indication of disease severity and impact
on quality of life (30, 31), and the ability
to assess its occurrence across all ages
after new-onset P. aeruginosa infection for
all subjects (unlike pulmonary function,
which was only available for 41% of
our cohort at the time of new-onset
P. aeruginosa). The 2-year observation
period was chosen based on availability
of clinical data after assessment of the
last isolates phenotyped in this study,
representing a proximal window of
clinical relevance. Additionally, although
pulmonary exacerbations have been
associated with both short- and long-term
morbidity and mortality (9, 32, 33), less is
understood about the associations between
rate of decline in lung function and
long-term outcomes, such as mortality,
in part because of complexities in model
development (34).
Table 3. Results from the Multivariable Model for the Association between Phenotypes
and the Emergence or Reappearance of Mucoidy over the Following Two Years
Odds Ratio 95% CI P Value
Mucoidy
Nonmucoid — — —
Mucoid 6.04 4.14–8.81 ,0.001
Increased growth in nitrate
Absent — — —
Present 2.37 1.65–3.40 ,0.001
b-Lactamase activity
Absent — — —
Present 1.68 1.20–2.34 ,0.001
Time from new-onset infection, yr 1.31 1.21–1.41 ,0.001
Definition of abbreviation: CI = confidence interval.
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Our study found mucoidy to be the
in vitro phenotype most significantly
associated with risk of a subsequent
pulmonary exacerbation regardless of
infection stage. However, reduced twitching
motility, which was more common and also
better distinguished infection stage than
mucoidy in this study, was also significantly
associated with risk of exacerbation.
Although mucoidy is often simple to
identify, the expression of this phenotype
can vary with culture conditions and can
revert over time (35). Additional analyses
from our cohort demonstrated that during
persistent infection, 58% of participants
with mucoid isolates maintained this
phenotype in a second culture sampled
within the year; in contrast, 65 and 75%
of participants with persistent infection
who had isolates with reduced twitching
and swimming present, respectively,
maintained these phenotypes in a second
culture within the year, highlighting the
relative stability of the latter motility
phenotypes. Because motility measures
can be reproducibly and quantitatively
measured, twitching motility represents
a promising candidate biomarker. Defective
motility (both twitching and swimming)
was observed previously in isolates from
late versus early CF infections, a change
that favors aggregation and may confer
protection against antibiotics and host
immunity (15, 36). Importantly, a recent
analysis (26) found a significant association
between P. aeruginosa acquisition and risk
of exacerbation, but not decline in lung
function in the EPIC Observational Study
cohort, supporting a relatively strong
relationship between P. aeruginosa and
exacerbations.
Given this finding, it is perhaps less
surprising that those phenotypes most
associated with risk of exacerbation were not
significantly associated with lung function
outcomes. Notably, our findings differed
from those of Li and coworkers (10),
who reported an association between the
transition from nonmucoid to mucoid
P. aeruginosa and faster rate of lung
function decline among children with CF
from the Wisconsin Newborn Screening
Study. This single-center study followed 56
children born between 1985 and 2004 from
birth to 16 years of age. There are several
potential explanations for this discrepancy.
First, the current 2-year follow-up period
may have been too short to clearly assess
lung function decline, because the
availability of spirometric data subsequent
to the emergence of mucoidy was
limited. By contrast, the average follow-up
time was 16 years for a recent, expanded
Wisconsin study that found mucoidy
to be a significant predictor of worsening
lung function (37). Second, our cohort
represents a more diverse and contemporary
cohort than that studied by Li and
colleagues, and CF antimicrobial strategies
have evolved in the interim. Not only
was tobramycin inhalation therapy
approved in 1998 (38), but aggressive
early P. aeruginosa eradication approaches
have become standard of care (39).
In contrast with lung function, we
identified a significant relationship between
mucoidy and exacerbations that was
consistent across infection stage. This
finding was not reported in prior
longitudinal observational studies (10, 37).
Because of the clinical significance of
mucoidy, we sought other phenotypes
that correlated with the subsequent
development of mucoidy. Two phenotypes,
increased growth in added nitrate and
b-lactamase production, were significantly
associated with subsequent mucoidy
regardless of infection stage. Altered nitrate
use was shown previously to be conferred
by at least two other adaptive changes in
chronic CF P. aeruginosa isolates: lasR
mutation (40) and mucoidy (41). Increased
b-lactamase production has been observed
in late versus early CF isolates both
caused by lasR mutation (40) and b-lactam
treatment (42). Thus, these phenotypic
changes may represent earlier prognostic
markers of important CF outcomes and
be relevant targets for novel, early
interventional strategies.
Our study had several strengths,
including a large, diverse cohort and
the relatively large numbers of both
P. aeruginosa isolates and in vitro
phenotypes characterized longitudinally
over the course of infection. In addition,
most phenotypic assays used were
quantitative rather than qualitative, limiting
bias. However, there were several notable
limitations. First, the epidemiologic nature
of this study prevents us from concluding
that the associations we found between
phenotypes and outcomes are causal. We
can conclude that these associations were
not simply driven by higher prevalences of
phenotypes during later stages of infection
because our models adjusted for time
from new-onset P. aeruginosa, a surrogate
for several measures of disease severity that
could represent potential confounders that
may be in the causal pathway.
Second, our analyses used data from
the CFFNPR, restricting the pulmonary
exacerbation events that were recorded
to those requiring IV antibiotics and/or
hospitalization. It was possible that
physicians were more likely to prescribe IV
antibiotics for specific symptoms if a patient
was known to have mucoidy; however,
in a survey of centers participating in the
EPIC Observational Study, most physicians
did not indicate their treatment preferences
to be influenced by the presence of mucoidy
(M. Rosenfeld, personal communication).
Furthermore, the practicality of assessing
more than 2,500 P. aeruginosa isolates
limited the number and types of phenotypes
assessed. Several other P. aeruginosa
characteristics have previously been found
to change throughout infection that we
did not assay, because of the difficulty of
adapting those assays for high-throughput
testing, expense, or poor reproducibility.
Among these characteristics are type III
secretion and cytotoxicity, metabolic
changes, antibiotic susceptibilities, growth
in sputum or anaerobically, hypermutability,
biofilm formation, membrane structural
changes, and serum sensitivity (12, 40, 43).
These characteristics represent potential
possibilities for future studies. Also, recent
analyses showed that traditional culture
methods (i.e., isolating a small number
of morphologically different bacterial
colonies from each culture) frequently
underrepresent the P. aeruginosa diversity
in individual samples of CF respiratory
secretions during chronic infection with
respect to several phenotypes (44–47);
therefore, even the large isolate collection
in this study likely undersampled the
phenotypic diversity of P. aeruginosa
in each subject. Similarly, it is possible
that sputum and OP specimens are not
sufficiently sensitive to reflect the earliest
stages of infection, whether of the lower
or upper airways (48, 49), potentially
explaining the observed high frequency
in our “early” isolates of phenotypes
commonly associated with adaptation.
Lastly, because of the EPIC Study
design, we were unable to capture isolates
from 100% of all P. aeruginosa–positive
cultures during the study, limiting our
ability to determine the exact timing of
the emergence of the phenotypes. Thus,
an unanswered question is whether specific
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clinical characteristics predict the
emergence of the key phenotypes identified
in our study, and in particular whether
antibiotic intensity or other factors over the
duration of infection favor P. aeruginosa
phenotypic adaptation. Unfortunately,
lack of detailed data regarding the timing
and frequency of antibiotic courses in this
observational study prohibited such an
analysis. Further research is therefore
needed to identify potential confounders
in the causal pathway that may help
to explain the associations between
P. aeruginosa phenotypes and clinical
outcomes.
In summary, P. aeruginosa undergoes
multiple phenotypic changes that are
associated with the transition from
early to chronic CF infection. Although
mucoidy remained one of two clinically
useful markers of risk of a pulmonary
exacerbation, two adaptive phenotypes
other than mucoidy emerged as candidate
markers of the transition to chronic
infection. The association between these
adaptive changes and progression of
infection and lung disease may indicate
important mechanisms of persistence
and pathogenesis. Thus, more research
is needed to identify novel therapeutic
approaches to prevent and eradicate
P. aeruginosa exhibiting mucoidy and other
adaptive changes. Phenotypic changes, such
as those identified in this study, have the
potential to provide valuable mechanistic
insight, and they may serve as clinically
useful markers of advanced infection or risk
of a pulmonary exacerbation, potentially
identifying patients who would benefit from
more aggressive treatment. n
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